Persistent müllerian duct syndrome (PMDS) is a rare form of male pseudohermaphroditism, characterized by the presence of a uterus and fallopian tubes owing to failure of müllerian duct regression in genotypically normal males. The association between a persistent müllerian duct and transverse testicular ectopia (TTE) is even more uncommon. PMDS with TTE is a very rare pathological association, often discovered during repair for inguinal hernia or cryptorchidism. We report 3 cases of Chinese patients with PMDS associated with TTE. Hysterectomy was performed, with resection of the underdeveloped fallopian tubes. Both gonads were placed into subdartos pouches in each scrotum by the transseptal approach. PMDS with TTE is a rarely encountered form of male pseudohermaphroditism usually unexpectedly found at surgery for cryptorchidism or inguinal hernia. Surgical treatment should avoid damage of fertile testes and vasa deferens.

Keywords:
Persistent müllerian duct syndrome, Transverse testicular ectopia, Pseudohermaphroditism
1.
Knebelmann B, Boussin L, Guerrier D: Anti-Müllerian hormone Bruxelles: a nonsense mutation associated with the persistent Müllerian duct syndrome. Proc Natl Acad Sci 1991;88:3767–3771.
2.
Loeff DS, Imbeaud S, Reyes HM, Meller JL: Surgical and genetic aspects of persistent müllerian duct syndrome. J Pediatr Surg 1994;29:61–65.
3.
Di Clemente N, Belville C: Anti-Müllerian hormone receptor defect. Best Pract Res Clin Endocrinol Metab 2006;20:599–610.
4.
Jordan M: Ein Fall von einseitigem Descensus testiculorum. Beitr Klin Chir 1895;15:245.
5.
Hutson JM, Chow CW, Ng W-D: Persistent müllerian duct syndrome with transverse testicular ectopia. Pediatr Surg Int 1987;2:191–194.
6.
Thompson ST, Grillis MA, Wolkoff LH: Transverse testicular ectopia in a man with persistent duct syndrome. Arch Pathol Lab Med 1994;118:752–755.
7.
Guerrier D, Tran D, van der Winden JM, et al: The persistent Müllerian duct syndrome: a molecular approach. J Clin Endocrinol Metab 1989;68:46–52.
8.
Sheehan SJ, Tobbia IN, Ismail MA: Persistent Müllerian duct syndrome. Review and report of 3 cases. Br J Urol 1985;57:548–551.
9.
Berkmen F, Alagol H: Germinal cell tumors of the testis in cryptorchids. J Exp Clin Cancer Res 1998;17:409–412.
10.
Manassero F, Cuttano MG, Morelli G: Mixed germ cell tumor after bilateral orchidopexy in persistent Müllerian duct syndrome with transverse testicular ectopia. Urol Int 2004;73:81–83.
11.
Melman A, Leiter E, Perez JM: The influence of neonatal orchiopexy upon the testis in persistent Müllerian duct syndrome. J Urol 1981;125:856–858.
12.
Giri SK, Berney D, O’Driscoll J: Choriocarcinoma with teratoma arising from an intra-abdominal testis in patient with persistent Müllerian duct syndrome. Lancet Oncol 2004;5:451–452.
13.
Eastham JA, McEvoy K, Sullivan R: A case of simultaneous bilateral nonseminomatous testicular tumors in persistent Müllerian duct syndrome. J Urol 1992;148:407–408.
14.
Vandersteen DR, Chaumet on AK, Ireland K: Surgical management of persistent müllerian duct syndrome. Urology 1997;49:941–945.
15.
Romero FR, Fucs M, Castro MG: Adenocarcinoma of persistent Müllerian duct remnants: case report and differential diagnosis. Urology 2005;66:194–195.
16.
Shinmura Y, Yokoi T, Tsutsui Y: A case of clear cell adenocarcinoma of the müllerian duct in persistent Müllerian duct syndrome the first reported case. Am J Surg Pathol 2002;26:1231–1234.
17.
Shirasaki Y, Nagai A, Nasu Y: Laparoscopic removal of Müllerian structures and orchiopexy for persistent Müllerian duct syndrome. Urology 2003;62:1121.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.